Pacific Edge takes testing online

Last updated 12:44 09/07/2014

Relevant offers


CentrePort 'plenty big enough' for public listing NZX-listed wine company Delegat Group opens office in Shanghai Temporary Jetstar terminal moved into place at New Plymouth Airport Matt Bowden's Stargate Operations owes more than $1.4m to creditors MBIE proposes more changes to reduce misuse of Financial Services register Vodafone apologises to fuming customers over internet outage in Wellington Did Coke influence anti-obesity group Global Energy Balance Network? Surge in new jobs sees Bay of Plenty unseat Auckland as strongest region Air New Zealand releases Airband monitoring bracelets for unaccompanied minors Electric car boom boosts coal power demand

Dunedin biotechnology company Pacific Edge will soon offer a urine-testing service for bladder cancer that can be ordered online.

Pacific Edge said today it would be launching the e-commerce platform on its website.

The urine samples would be analysed by the company's Dunedin laboratory.

Pacific Edge has developed a non-invasive technology for diagnosing bladder cancer and called it CXbladder.

Pacific Edge commercial director Brent Pownall said Pacific Edge wanted to provide a readily accessible service to those who had found blood in the urine, haematuria, one of the early indicators of possible bladder cancer.

A detailed test report would be sent to the person's general practitioner or nominated healthcare professional.

"Our goal is to make this technology as readily accessible as buying an icecream from the corner dairy," Pownall said.

The company said the e-commerce site had been approved by Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, and the Therapeutic Advertising Pre-vetting System of the Advertising Standards Authority.

In its statement to the NZX today, Pacific Edge did not reveal the cost of the test.

Pacific Edge's aim is to replace the "uncomfortable" cystoscopy method of detecting bladder cancer used by urologists with its non-invasive test.

It has set up its own testing labs in New Zealand and the United States, while in Australia and Spain it has licensed its technology to existing diagnostic companies.

Its sales of CXbladder have so far been low. The company estimates it could reach $100 million of sales by the end of five years of trading.

It launched the product in the United States a year ago and raised capital late last year to establish a United States sales force.

Government agency, Health Innovation Hub, in February announced it would help to raise awareness of the product.

CXbladder would be considered for use in clinics operated by Auckland, Waitemata, Counties Manukau and Canterbury district health boards, it said.

Ad Feedback

- The Press

Special offers

Featured Promotions

Sponsored Content